Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

2014262 citationsJournal Article

Authors

Tony W. Ho · Lund University

Kathryn M. Connor · Lund University

Ying Zhang · Lund University

Eric Pearlman · Mercer University

Janelle M. Koppenhaver · Mercer University

Xiaoyin Fan · Lund University

Christopher Lines · Mercer University

Abstract

This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per month compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.

Topics & Keywords

Migraine and Headache Studies Sympathectomy and Hyperhidrosis Treatments Trigeminal Neuralgia and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 83, Issue 11, pp. 958-966

DOI: 10.1212/wnl.0000000000000771

Field-Weighted Citation Impact: 16.51